Phibro is positioning itself as a long-term partner for poultry producers in Turkiye

06/01/2026

At Phibro Animal Health’s “Poultry Gut Health and Coccidiosis Management” seminar, Omer Diker, Phibro Animal Health Vice President for Europe-Middle East-North Africa, framed the company’s strategy around one idea: trust built over decades must translate into practical, solution-driven value in the field.

In his opening remarks, Diker linked Phibro’s legacy to its current scale and ambitions. He underlined that the company has been active since 1946, and noted that Phibro, founded in 1965, now operates across 95 countries. He also emphasized internal production capacity: 70% of products are manufactured in Phibro facilities with the support of 2,300 employees. Looking ahead, he stated a 2025 global target of USD 1.5 billion, while also marking Phibro Turkiye’s 14th year in the market.

For The Animal Economics audience, the business message is clear: Phibro wants to be seen not as a supplier, but as a structured solution partner for fast-growing poultry and cattle segments in Turkiye. Diker highlighted the value of a strong field technical team and a multi-option portfolio, positioning these as tools to help producers choose the “right” program for their animals and production targets.

In a post-seminar conversation focused on future outlook, Diker argued that coccidiosis should be treated not simply as a disease event, but as a performance management challenge that can disrupt the full production chain when not planned correctly. In his view, small mistakes in anticoccidial programming can create outsized field consequences, making planning, timing, and monitoring as important as product choice.

He also placed emphasis on the next phase of poultry health: preventive approaches, reduced antibiotic dependency, and data-driven flock management becoming standard. His closing message tied animal health to broader outcomes: food security, public health, and sustainability.